

## Lopressor® (metoprolol tartrate) – New formulation approval

- On April 10, 2025, the <u>FDA approved</u> Validus Pharmaceuticals' <u>Lopressor (metoprolol tartrate)</u> oral solution in adult patients:
  - For the treatment of hypertension, to lower blood pressure
  - In the long-term treatment of angina pectoris in adult patients, to reduce angina attacks and to improve exercise tolerance
  - In the treatment of hemodynamically stable patients with definite or suspected myocardial infarction, to reduce the risk of cardiovascular mortality when used alone or in conjunction with intravenous metoprolol therapy.
- Metoprolol tartrate is a beta-adrenergic blocker that is available generically as an oral tablet.
- Lopressor is contraindicated in severe bradycardia, second- or third-degree heart block, cardiogenic shock, systolic blood pressure < 100, decompensated heart failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product.
- Warnings and precautions for Lopressor include abrupt cessation of therapy, heart failure, bronchospastic disease, pheochromocytoma, major surgery, hypoglycemia, thyrotoxicosis, risk of anaphylactic reaction, and peripheral vascular disease.
- The most common adverse reactions with Lopressor use are tiredness, dizziness, depression, shortness of breath, bradycardia, hypotension, diarrhea, pruritus, and rash.
- Refer to the Lopressor drug label for complete dosing and administration recommendations.
- Validus Pharmaceuticals' launch plans for Lopressor are pending. Lopressor will be available as a 10 mg/mL oral solution.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.